Alkem Laboratories fell 2.5% to Rs 1,922 on BSE in otherwise strong market after the company said the US health regulator has inspected its Baddi plant and issued three observations on account of violation of good manufacturing norms.
“The US Food and Drug Administration (USFDA) had conducted an inspection at the company's manufacturing facility located at Baddi, India from 2nd March, 2017 to 10th March, 2017. In this regard, the company has received the inspection report which contains three 483 observations,” Alkem Laboratories said in exchange filing on March 10, 2017.
The company shall put together a detailed
“The US Food and Drug Administration (USFDA) had conducted an inspection at the company's manufacturing facility located at Baddi, India from 2nd March, 2017 to 10th March, 2017. In this regard, the company has received the inspection report which contains three 483 observations,” Alkem Laboratories said in exchange filing on March 10, 2017.
The company shall put together a detailed

)